Missed Phase II endpoint but promising signs for tivantinib in colorectal cancer
This article was originally published in Scrip
Executive Summary
ArQule's lead product candidate tivantinib (ARQ 197) has hit another bump on its road to market, this time in the colorectal cancer setting where it has missed the primary endpoint in a Phase II international trial.